Osteonecrosis of the jaw in a metastatic lung cancer patient with bone metastases undergoing pembrolizumab + denosumab combination therapy: Case report and literature review
Osteonecrosis of the jaw in a metastatic lung cancer patient with bone metastases undergoing pembrolizumab + denosumab combination therapy: Case report and literature review
复制标题
接受派姆单抗地诺单抗联合治疗的转移性肺癌骨转移患者颌骨骨坏死：病例报告及文献复习
DOI：
10.1016/j.oraloncology.2020.104874
复制
发表时间：
2020
期刊：
影响因子：
4.8
通讯作者：
Toratani Shigeaki
中科院分区：
文献类型：
--
作者：
Myoken Yoshinari;Fujita Yoshinori;Kawamoto Kazuma;Toratani Shigeaki
罕见的药物不良反应 MRONJ（药物相关性颌骨坏死）可由抗骨吸收剂、抗血管生成剂或免疫调节剂治疗引起。免疫检查点抑制剂（ICIs；例如派姆单抗）是晚期或转移性癌症患者的标准治疗方法。针对 NF-kB 配体受体激活剂 (RANKL) 的地诺单抗被批准用于预防骨转移癌症患者的骨骼相关事件 (SRE)。 ICI + 狄诺塞麦的联合治疗在转移性黑色素瘤和骨转移肺癌患者中显示出良好的疗效，并且没有意外的安全性问题。我们介绍了一名患有转移性肺癌和骨转移的成年女性晚期下颌骨坏死的罕见病例，她同时接受了派姆单抗 + 狄诺塞麦治疗。
The rare adverse drug reaction MRONJ (medication-related osteonecrosis of the jaw) can be induced by treatment with antiresorptive, antiangiogenic, or immunomodulating agents. Immune checkpoint inhibitors (ICIs; e.g., pembrolizumab) are the standard care for advanced or metastatic cancer patients. Denosumab directed against receptor activator of NF-kB ligand (RANKL) is approved for preventing skeletal-related events (SREs) in cancer patients with bone metastases. The combination therapy of ICIs + denosumab has shown promising efficacy and no unexpected safety issues in metastatic melanoma and lung cancer patients with bone metastases. We present a rare case of advanced mandibular osteonecrosis in an adult female with metastatic lung cancer and bone metastases who received concomitant pembrolizumab + denosumab.